Galecto Stock Today

GLTO Stock  USD 24.98  1.03  4.30%   

Performance

Fair

 
Weak
 
Strong

Odds Of Distress

Average

 
High
 
Low
Galecto is selling at 24.98 as of the 18th of January 2026; that is 4.30 percent increase since the beginning of the trading day. The stock's open price was 23.95. Galecto has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2025 and ending today, the 18th of January 2026. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
29th of October 2020
Category
Healthcare
Classification
Health Care
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts. Galecto operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.59 M outstanding shares of which 172.44 K shares are currently shorted by private and institutional investors with about 0.12 trading days to cover. More on Galecto

Moving together with Galecto Stock

  0.67AMGN Amgen IncPairCorr
  0.62BOF BranchOut Food CommonPairCorr

Moving against Galecto Stock

  0.62HPQ HP IncPairCorr
  0.61LIPO Lipella PharmaceuticalsPairCorr
  0.59HD Home DepotPairCorr

Galecto Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current LiabilitiesM1.1 M
Notably Down
Pretty Stable
Total Assets14.6 M15.4 M
Notably Down
Very volatile
Total Current Assets14.4 M15.2 M
Notably Down
Very volatile
Debt Levels
Galecto can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Galecto's financial leverage. It provides some insight into what part of Galecto's total assets is financed by creditors.
Liquidity
Galecto currently holds 73 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Galecto has a current ratio of 10.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Galecto's use of debt, we should always consider it together with its cash and equity.

Total Cashflows From Investing Activities

14.07 Million
Galecto (GLTO) is traded on NASDAQ Exchange in USA and employs 5 people. Galecto is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 43.73 M. Galecto conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.59 M outstanding shares of which 172.44 K shares are currently shorted by private and institutional investors with about 0.12 trading days to cover. Galecto currently holds about 79.03 M in cash with (18.62 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.11.
Check Galecto Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Galecto is $43.73 Million. Galecto retains 3.56 (percent) of its outstanding shares held by insiders and 13.38 (percent) owned by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Galecto Ownership Details

Galecto Stock Institutional Holders

InstituionRecorded OnShares
Jpmorgan Chase & Co2025-03-31
0.0
Squarepoint Ops Llc2025-06-30
0.0
Novo A/s2025-06-30
99.9 K
Renaissance Technologies Corp2025-06-30
14.5 K
Susquehanna International Group, Llp2025-06-30
13.6 K
Ubs Group Ag2025-06-30
2.3 K
Bank Of America Corp2025-06-30
1.2 K
Tower Research Capital Llc2025-06-30
942
Blackrock Inc2025-06-30
100.0
Barclays Plc2025-06-30
100.0
Sbi Securities Co Ltd2025-06-30
18.0
View Galecto Diagnostics

Galecto Historical Income Statement

At this time, Galecto's Total Other Income Expense Net is very stable compared to the past year. As of the 18th of January 2026, Cost Of Revenue is likely to grow to about 5.3 M, while Selling General Administrative is likely to drop about 10.1 M. View More Fundamentals

Galecto Stock Against Markets

Galecto Corporate Management

Matthew KronmillerEVP OfficerProfile
CPA CPAChief OfficerProfile
Becker MDChief OfficerProfile
Pr MDChief OfficerProfile
Ulf NilssonCoFounderProfile
When determining whether Galecto offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Galecto's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Galecto Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Galecto Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Galecto. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
To learn how to invest in Galecto Stock, please use our How to Invest in Galecto guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galecto. If investors know Galecto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galecto listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.11)
Return On Assets
(0.44)
Return On Equity
(1.09)
The market value of Galecto is measured differently than its book value, which is the value of Galecto that is recorded on the company's balance sheet. Investors also form their own opinion of Galecto's value that differs from its market value or its book value, called intrinsic value, which is Galecto's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galecto's market value can be influenced by many factors that don't directly affect Galecto's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galecto's value and its price as these two are different measures arrived at by different means. Investors typically determine if Galecto is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galecto's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.